查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2095650

癌症免疫療法藥物研發外包市場－2026-2032年全球市場預測

Cancer Immunotherapy Drug Discovery Outsourcing Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，癌症免疫療法藥物研發外包市場規模將達到 32.1 億美元，複合年成長率為 10.33%。

主要市場統計數據
基準年 2025 16.1億美元
預計年份：2026年 17.7億美元
預測年份 2032 32.1億美元
複合年成長率 (%) 10.33%

癌症免疫療法藥物研發外包正成為生物製藥創新者尋求快速獲取專業腫瘤學、轉化免疫學、生物資訊學、檢測方法開發、藥物化學、生技藥品工程以及臨床實施能力的策略性商業模式。隨著免疫腫瘤學研發管線從免疫查核點抑制劑擴展到包括雙特異性抗體、抗體藥物複合體(ADC)、細胞療法、癌症疫苗、細胞激素工程、固有免疫調節劑和微生物組相關療法，申辦方越來越依賴外部藥物研發合作夥伴來應對複雜的科學挑戰、減少對固定基礎設施的需求並獲取稀缺的技術人才。這種外包模式在早期藥物發現、標靶檢驗、生物標記鑑定、免疫分析、臨床前藥理學、毒理學、CMC響應計劃以及跨多體學平台的數據整合等方面尤為有效。全球癌症負擔日益加重、精準腫瘤學投資不斷增加，以及對持續療效、患者分層和更高安全性的需求，都進一步推動了這項需求。在此背景下，成功的業務外包不僅需要具備執行任務的能力，還需要整合的科學合作、品管系統、符合監管要求以及數據驅動的決策。這使得免疫療法候選藥物能夠更有信心地從概念階段過渡到臨床試驗準備階段。

癌症免疫療法外包環境的變革性變化

癌症免疫療法的外包格局正在轉變，從單純基於處理能力的服務採購轉向以轉化終點為中心的整合式藥物研發夥伴關係。申辦方越來越傾向於尋求能夠整合濕實驗室免疫學、計算生物學、生物標記策略、人源化模型系統、高內涵篩檢和監管文件支援等服務的合作夥伴。這反映了免疫療法機制的複雜性，顯示需要從整體而非順序的角度評估標靶生物學、腫瘤微環境行為、免疫逃脫途徑和患者異質性。另一個重大轉變是擴大使用高度人源化的平台，例如類器官、腫瘤晶片系統、單細胞定序、空間生物學和免疫細胞共培養分析，以提高臨床前研究的預測準確性。監管機構對資料完整性、可重複性和可追溯性的要求，尤其是在生技藥品、細胞療法和聯合治療領域，也正在影響外包決策。同時，地緣政治供應鏈問題以及對具有韌性的多區域發展網路的需求，促使贊助商在保持標準化品質和管治模式的同時，實現供應商地點的多元化。

人工智慧對免疫腫瘤藥物發現的累積影響

人工智慧 (AI) 透過改善標靶優先排序、表位預測、累積先導化合物最佳化、生物標記發現、患者分層和假設生成，對癌症免疫療法的整個外包藥物研發流程產生了累積性影響，從而推動了臨床試驗的開展。 AI 驅動的分析可以整合基因組、轉錄組、蛋白質組、影像和臨床資料集，以識別與療效和抗藥性相關的免疫特徵。同時，機器學習模型可以輔助進行新抗原預測、抗體設計、蛋白質結構評估和毒性風險篩檢。在外包藥物研發專案中，這些工具正被擴大用於減少實驗重複、加速候選化合物篩選，並在成本高昂的檢驗階段之前強化證據包。然而，AI 的價值取決於檢驗的資料集、透明的模型管治、偏差評估和實驗室驗證。在腫瘤免疫學計畫中，AI 的輸出需要與具有生物學意義的檢測和臨床相關的終點相關聯，尤其因為腫瘤-免疫系統相互作用會因適應症、分期、治療史和患者群體的不同而有所差異。因此，將計算科學專業知識與檢驗的實驗平台相結合的外包合作夥伴更有能力提供更強大的轉換性見解。同時，贊助商必須確保明確的資料所有權、網路安全措施、可復現的工作流程，並遵守不斷發展的人工智慧和生命科學法規。

全球免疫療法外包中心的關鍵區域見解

亞太地區正透過不斷完善的生物醫學基礎設施、大規模的癌症患者群體、經濟高效的研究運作以及對生技藥品、細胞療法、基因組學和臨床應用領域日益成長的投資，加強其在免疫療法藥物研發外包領域的作用。該地區充分利用了中國、印度、日本、韓國和澳洲等國家強大的科學研究實力，並依托學術腫瘤學網路、國家級精準醫療舉措和監管現代化進程。歐洲透過跨國研究計畫、嚴格的監管標準、先進的腫瘤學中心以及在細胞療法、抗體平台和真實世界數據（RWE）生成方面的專業知識，為免疫療法藥物研發外包提供了良好的環境。北美憑藉其研究機構的集中、成熟的公共和私人資金籌措管道、先進的臨床試驗生態系統以及在生技藥品工程、轉化生物標記和監管科學方面的雄厚實力，仍然是免疫腫瘤學創新的重要中心。拉丁美洲在支持腫瘤學研究和協調臨床開發方面的重要性日益凸顯，這得益於其多元化的患者群體、不斷完善的臨床試驗基礎設施以及對全球腫瘤學研究日益成長的參與度。然而，監管時間表和基礎設施成熟度的差異仍然是外包策略中的關鍵考慮因素。非洲擁有長期發展潛力，這得益於其未被滿足的需求、遺傳多樣性和不斷擴展的研究網路，但外包模式必須考慮基礎設施差異、倫理管治、人力資源開發和公平的夥伴關係關係等議題。在中東，對醫療保健和生物技術的投資正在不斷成長，一些市場正在發展基因組學計畫、腫瘤中心和臨床研究機構，這些機構能夠支持跨區域合作。

免疫腫瘤學外包策略的關鍵小組見解

北約成員國與成熟的生物醫學生態系統高度重合，並受益於網路安全、供應鏈韌性和資料管治的健全標準。隨著外包免疫腫瘤計畫依賴安全的跨國數據交換和穩健的研究網路，這些標準的重要性日益凸顯。七國集團（G7）憑藉先進的研究基礎設施、完善的監管機構、深厚的腫瘤學專業知識以及對人工智慧、多體學和精準醫療工具的積極應用，持續引領高階癌症免疫療法的發現。歐盟擁有統一的藥品法規、強大的產學合作、資料保護標準以及促進先進生物標記和細胞療法開發的跨境研究資金，為免疫腫瘤外包提供了一個結構完善的環境。金磚國家擁有大規模的患者群體、不斷壯大的科研人員隊伍、日益增強的生技藥品研發能力以及政府主導的創新舉措，為藥物發現和轉化研究外包提供了巨大的機會。然而，贊助公司必須應對智慧財產權保護、監管路徑和品管成熟度方面的差異。隨著東協成員國加大對生醫製造、臨床研究能力、數位醫療和舉措協調的投入，東南亞國協在癌症免疫療法外包領域的重要性日益凸顯。這同時也帶來了成本效益高的營運模式以及接觸多元化患者群的機會。海灣合作理事會（GCC）成員國對於未來的轉化研究夥伴關係和區域臨床試驗網路具有重要的戰略意義，因為它們正透過國家衛生轉型計畫、基因組學計劃以及對專業醫療城市的投資，大力發展癌症治療和生命科學領域的基礎設施。

關鍵國家對癌症免疫療法藥物研發外包的洞察

美國在先進免疫腫瘤學外包需求方面佔據領先地位，這得益於其主導的癌症研究中心網路、生物技術資金、專業合約研究組織 (CRO) 和合約研發生產組織 (CDMO) 的能力，以及在新型生技藥品、細胞療法和聯合癌症治療產品方面的監管經驗。中國正在迅速擴大其免疫腫瘤學研究基礎、生技藥品生產能力和臨床試驗活動，使其成為重要的外包目的地，但必須密切關注數據、監管和地緣政治風險。德國在生技藥品、工程、精準診斷和受監管的生命科學研究方面擁有先進的能力，而日本在高品質轉化科學、腫瘤創新和嚴格的管理體制方面繼續發揮著重要作用。印度提供具成本效益的藥物研發服務、化學專業知識、生物資訊人才以及不斷擴展的生技藥品和臨床研究能力。英國憑藉其基因組醫學計劃、強大的腫瘤臨床試驗基礎設施和卓越的轉化研究，在癌症免疫療法藥物研發領域仍具有影響力。同時，法國憑藉其強大的公共研究機構和醫院網路，支持免疫學、腫瘤學和細胞療法領域的創新。加拿大憑藉其強大的腫瘤學學術研究、免疫學專業知識、公共研究經費和合作轉化研究網路，為生物標記和早期藥物發現夥伴關係提供了有力支持，使其成為極具吸引力的選擇。澳洲因其早期腫瘤學研究、臨床試驗獎勵和健全的生物醫學管治而備受青睞。巴西在拉丁美洲脫穎而出，其腫瘤患者的多樣性、臨床研究活動和科學研究能力都十分突出，但申辦方仍需應對監管和營運方面的複雜性。義大利和西班牙擁有成熟的腫瘤學研究生態系統、經驗豐富的臨床試驗中心，並積極參與先進療法的研發。墨西哥得益於與北美申辦者的地理位置接近性以及不斷完善的醫療保健研究生態系統，正在加強其在臨床研究合作和區域外包支援方面的作用。韓國憑藉其先進的醫院、政府創新計劃和高品質的生產能力，正在崛起成為生技藥品、細胞療法、數位醫療和腫瘤學研究的領先中心。雖然俄羅斯在生物學和化學領域擁有強大的科學實力，但地緣政治、監管和供應鏈的因素對俄羅斯的外包決策產生了重大影響。

為行業領導者提供的實用建議

產業領導者應將癌症免疫療法藥物研發外包視為一項策略能力，而不僅僅是採購職能。申辦方應根據合作夥伴是否具備以下條件來選擇合作方：檢驗的免疫學平台、腫瘤學專業知識、數據完整性管理系統、規範的監管文件流程，以及將藥物研發生物學與轉化生物標記相結合的能力。多元化的外包網路可以降低營運風險，但這些風險必須透過標準化流程、品質協議、網路安全要求和明確的智慧財產權條款進行管理。各機構應優先考慮那些整合了人工智慧和實驗室檢驗能力的合作夥伴，尤其是在標靶發現、抗體工程、新抗原預測、免疫分析和主導生物標記的患者分層方面。領導者還需要根據可重複性、與人體相關的檢測性能、毒性訊號、可生產性和臨床差異化等因素來建立決策查核點點。對於細胞療法、雙特異性抗體和個人化疫苗等複雜療法，藥物研發、CMC、監管和臨床團隊之間的早期合作至關重要。最後，贊助者應建立一個符合倫理且包容的研究框架，以提高免疫腫瘤學資料集的代表性，並支持負責任的全球合作。

調查方法

本執行摘要採用結構化的二手研究方法撰寫，使用了與癌症免疫療法、腫瘤藥物研發、外包模式、監管科學、生命科學領域的調查方法以及區域生物醫學生態系統相關的檢驗的公共領域和機構資料。該方法強調對來自同行評審的科學文獻、衛生監管機構指南、臨床研究註冊庫、政府生物技術戰略、癌症負擔出版物、公開的監管文件以及權威的醫療保健和生命科學政策資訊來源的證據進行三角驗證。檢驗對各種見解進行定性整合，以識別技術演進、區域能力、外包促進因素、管治考量和策略意義，而無需使用市場規模、市場佔有率或預測數據。數據解讀著重於可觀察的產業趨勢、已確立的科學進展、監管預期和已記錄的區域能力指標。這種調查方法排除了檢驗的說法，避免了宣傳性聲明，確保結論是基於可靠的證據，並適用於免疫腫瘤外包策略的經營團隊決策。

結論

對於那些希望推進複雜腫瘤計畫並充分利用專業科學、計算和轉化能力的機構而言，癌症免疫療法藥物研發外包正逐漸成為至關重要的策略。這一領域的發展受到以下因素的影響：對腫瘤和免疫生物學理解的不斷加深、人工智慧和多組體學的快速進步、全球研究基礎設施的不斷擴展，以及對可重複性、品質和監管合規性日益成長的期望。在區域和國家層面，成熟的研發中心對於高階創新仍然至關重要，而新興地區則憑藉其臨床多樣性、成本效益以及對生命科學的定向投資，正在擴大自身的角色。為了取得成功，產業領導者必須建立一個整合卓越科學、檢驗的資料工作流程、安全協作、符合倫理的研究實踐和早期轉化規劃的外包生態系統。在臨床差異化取決於準確性、持久性和安全性的領域，最有效的外包策略是將全球覆蓋範圍與嚴格的管治和實證決策相結合。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：癌症免疫療法藥物研發外包市場：依服務類型分類

  • 臨床開發服務
  • 數據管理和生物統計學
    • 生物資訊學
    • 臨床數據管理
    • 統計分析
  • 製造支持
    • CMC最佳化
    • 製程開發
  • 臨床前服務
    • 命中率和潛在客戶開發
    • 先導藥物最適化
    • 臨床前安全性評估
    • 目標識別
  • 藥物支持
    • IND申請支持
    • 監理策略諮詢

第8章：癌症免疫療法藥物研發外包市場：依治療方式分類

  • 癌症疫苗
    • 樹突細胞疫苗
    • DNA疫苗
    • 胜肽疫苗
    • RNA疫苗
  • CAR-T細胞療法
    • BCMA標靶
    • CD19標靶
  • 查核點抑制劑
    • CTLA-4抑制劑
    • PD-1抑制劑
    • PD-L1抑制劑
  • 細胞激素療法
    • 集落刺激因子
    • 干擾素
    • 白細胞介素
  • 單株抗體
    • 嵌合體
    • 完全人類
    • 人性化
    • 小鼠來源
  • 溶瘤病毒療法
    • 基於腺病毒的
    • HSV 基礎
    • 基於呼腸孤病毒

第9章：癌症免疫療法藥物研發外包市場：依工作流程階段分類

  • 早期藥物發現
  • 先導藥物最適化
  • 臨床前開發

第10章：癌症免疫療法藥物研發外包市場：依分子類型分類

  • 抗體衍生分子
  • 細胞衍生產品
  • 基因改造產品
  • 基於胜肽和蛋白質的療法
  • 低分子化合物
  • 基於核酸的治療藥物

第11章：癌症免疫療法藥物研發外包市場：以藥物研發平台分類

  • 體外藥物發現平台
  • 體內藥物發現平台
  • ExVivo平台
  • In Silico平台

第12章：癌症免疫療法藥物研發外包市場：依外包模式分類

  • 全方位外包
  • 根據功能將服務外包給服務供應商
  • 企劃為基礎的外包
  • 透過策略夥伴關係進行外包
  • 由專門的調查團隊進行外包

第13章：癌症免疫療法藥物研發外包市場：依最終用戶分類

  • 學術研究機構
  • 生技公司
  • 政府附屬研究機構
  • 製藥公司

第14章：癌症免疫療法藥物研發外包市場：依治療領域分類

  • 固體癌
    • 肺癌
    • 乳癌
    • 結腸癌
    • 黑色素瘤
    • 攝護腺癌
    • 胃癌
    • 肝癌
    • 卵巢癌
    • 胰臟癌
    • 腦腫瘤
  • 骨髓惡性腫瘤
    • 淋巴瘤
    • 多發性骨髓瘤
    • 骨髓發育不良症候群
    • 白血病

第15章：癌症免疫療法藥物研發外包市場：依地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第16章：癌症免疫療法藥物研發外包市場：依組別分類

  • NATO
  • G7
  • EU
  • BRICS
  • ASEAN
  • GCC

第17章：癌症免疫療法藥物研發外包市場：依國家分類

  • 美國
  • 中國
  • 德國
  • 日本
  • 印度
  • 英國
  • 法國
  • 加拿大
  • 澳洲
  • 巴西
  • 義大利
  • 墨西哥
  • 韓國
  • 俄羅斯
  • 西班牙

第18章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第19章：公司簡介

  • AbCellera Biologics Inc.
  • Absci Corporation
  • Adimab, LLC
  • Alloy Therapeutics, Inc.
  • Anthem Biosciences Limited
  • Aragen Life Sciences Limited
  • Champions Oncology, Inc.
  • Charles River Laboratories International, Inc.
  • ChemDiv, Inc.
  • Creative Biolabs, Inc.
  • Curia Global, Inc.
  • Domainex Ltd.
  • Enamine Ltd.
  • Eurofins Scientific SE
  • Evotec SE
  • GenScript Biotech Corporation
  • ImmunoPrecise Antibodies Ltd.
  • InSilico Medicine
  • JSR Corporation
  • NovAliX SAS
  • Pharmaron Beijing Co., Ltd.
  • ProMab Biotechnologies, Inc.
  • Reaction Biology Corporation
  • Sai Life Sciences Limited
  • Schrodinger, Inc.
  • Selvita SA
  • Shanghai Medicilon Inc.
  • Sygnature Discovery Limited
  • Syngene International Limited
  • Taconic Biosciences, Inc.
  • TCG Lifesciences Limited
  • The Jackson Laboratory
  • WuXi AppTec Co., Ltd.
  • WuXi Biologics（Cayman）Inc.
  • XtalPi Holdings Limited
Product Code: MRR-205091A88709

The Cancer Immunotherapy Drug Discovery Outsourcing Market is projected to grow by USD 3.21 billion at a CAGR of 10.33% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.61 billion
Estimated Year [2026] USD 1.77 billion
Forecast Year [2032] USD 3.21 billion
CAGR (%) 10.33%

Cancer immunotherapy drug discovery outsourcing is becoming a strategic operating model for biopharmaceutical innovators seeking faster access to specialized oncology biology, translational immunology, bioinformatics, assay development, medicinal chemistry, biologics engineering, and clinical-enabling capabilities. As immuno-oncology pipelines expand beyond checkpoint inhibition into bispecific antibodies, antibody-drug conjugates, cell therapies, cancer vaccines, cytokine engineering, innate immune modulators, and microbiome-linked approaches, sponsors increasingly rely on external discovery partners to manage scientific complexity, control fixed infrastructure needs, and access scarce technical talent. The outsourcing model is especially relevant in early discovery, target validation, biomarker identification, immune profiling, preclinical pharmacology, toxicology, CMC-readiness planning, and data integration across multi-omics platforms. Demand is reinforced by the continued global burden of cancer, rising investment in precision oncology, and the need to improve response durability, patient stratification, and safety profiles. Within this environment, successful outsourcing is less about transactional capacity and more about integrated scientific collaboration, quality systems, regulatory alignment, and data-rich decision-making that can move immunotherapy candidates from concept to investigational readiness with greater confidence.

Transformative Shifts in the Cancer Immunotherapy Outsourcing Landscape

The cancer immunotherapy outsourcing landscape is undergoing a shift from capacity-based service procurement toward integrated discovery partnerships built around translational endpoints. Sponsors are increasingly seeking partners that combine wet-lab immunology, computational biology, biomarker strategy, humanized model systems, high-content screening, and regulatory documentation support. This reflects the complexity of immunotherapy mechanisms, where target biology, tumor microenvironment behavior, immune escape pathways, and patient heterogeneity must be assessed together rather than sequentially. Another major transformation is the growing use of human-relevant platforms, including organoids, tumor-on-chip systems, single-cell sequencing, spatial biology, and immune cell co-culture assays, to improve the predictive value of preclinical research. Outsourcing decisions are also being shaped by regulatory expectations for data integrity, reproducibility, and traceability, particularly in biologics, cell-based therapies, and combination regimens. At the same time, geopolitical supply chain concerns and the need for resilient multi-region development networks are encouraging sponsors to diversify vendor footprints while maintaining standardized quality and governance models.

Cumulative Impact of Artificial Intelligence on Immuno-Oncology Discovery

Artificial intelligence is creating a cumulative impact across cancer immunotherapy drug discovery outsourcing by improving target prioritization, epitope prediction, lead optimization, biomarker discovery, patient stratification, and trial-enabling hypothesis generation. AI-enabled analytics can integrate genomic, transcriptomic, proteomic, imaging, and clinical datasets to identify immune signatures associated with response or resistance, while machine learning models support neoantigen prediction, antibody design, protein structure assessment, and toxicity risk screening. In outsourced discovery programs, these tools are increasingly used to reduce experimental redundancy, accelerate candidate triage, and strengthen evidence packages before costly validation stages. However, the value of AI depends on verified datasets, transparent model governance, bias assessment, and laboratory confirmation. For immuno-oncology programs, AI outputs must be connected to biologically meaningful assays and clinically relevant endpoints, especially because tumor immune interactions vary by indication, stage, prior therapy, and patient population. Outsourcing partners that combine computational expertise with validated experimental platforms are therefore positioned to deliver stronger translational insight, while sponsors must ensure clear data ownership, cybersecurity controls, reproducible workflows, and compliance with evolving AI and life sciences regulations.

Key Regional Insights Across Global Immunotherapy Outsourcing Hubs

Asia-Pacific is strengthening its role in cancer immunotherapy drug discovery outsourcing through expanding biomedical infrastructure, large oncology patient populations, cost-efficient research operations, and increasing investment in biologics, cell therapy, genomics, and clinical translation. The region benefits from strong scientific capabilities in countries such as China, India, Japan, South Korea, and Australia, supported by academic oncology networks, national precision medicine initiatives, and regulatory modernization. Europe offers a robust environment for immunotherapy discovery outsourcing through cross-border research programs, strong regulatory standards, advanced oncology centers, and expertise in cell therapy, antibody platforms, and real-world evidence generation. North America remains a high-value hub for immuno-oncology innovation due to its concentration of research institutions, mature public and private funding channels, advanced clinical trial ecosystems, and strong expertise in biologics engineering, translational biomarkers, and regulatory science. Latin America is gaining relevance for oncology research support and clinical development connectivity, driven by diverse patient populations, improving trial infrastructure, and increasing participation in global oncology studies, though variability in regulatory timelines and infrastructure maturity remains important for outsourcing strategy. Africa presents long-term potential due to unmet oncology needs, genetic diversity, and growing research networks, but outsourcing models must account for infrastructure gaps, ethics governance, workforce development, and equitable partnership requirements. The Middle East is expanding healthcare and biotechnology investment, with select markets building genomics programs, oncology centers, and clinical research capacity that can support regional collaboration.

Key Group Insights for Immuno-Oncology Outsourcing Strategy

NATO countries overlap significantly with mature biomedical ecosystems and benefit from strong standards in cybersecurity, supply chain resilience, and data governance, which are increasingly relevant as outsourced immuno-oncology programs depend on secure cross-border data exchange and resilient research networks. G7 countries continue to anchor high-end cancer immunotherapy discovery through advanced research infrastructure, established regulatory agencies, deep oncology expertise, and strong adoption of AI, multi-omics, and precision medicine tools. The European Union provides a highly structured environment for immuno-oncology outsourcing, supported by harmonized medicine regulation, strong academic-industry collaboration, data protection standards, and cross-border research funding that encourages advanced biomarker and cell therapy development. BRICS economies collectively represent a major opportunity for discovery and translational outsourcing because they combine large patient bases, expanding scientific workforces, increasing biologics capabilities, and government-backed innovation agendas, although sponsors must navigate differences in intellectual property enforcement, regulatory pathways, and quality maturity. ASEAN is becoming increasingly relevant for cancer immunotherapy outsourcing as member economies invest in biomedical manufacturing, clinical research capacity, digital health, and regulatory harmonization efforts, with opportunities tied to cost-effective operations and access to diverse patient populations. The GCC is advancing oncology care and life sciences infrastructure through national health transformation agendas, genomics initiatives, and investment in specialized medical cities, making the group strategically important for future translational research partnerships and regional trial networks.

Key Country Insights for Cancer Immunotherapy Discovery Outsourcing

The United States leads in advanced immuno-oncology outsourcing demand due to its dense network of cancer research centers, biotechnology funding, specialized CRO and CDMO capabilities, and regulatory experience with novel biologics, cell therapies, and combination oncology products. China has rapidly expanded its immuno-oncology research base, biologics manufacturing capacity, and clinical trial activity, making it a major outsourcing destination while requiring careful attention to data, regulatory, and geopolitical risk. Germany offers deep capabilities in biologics, engineering, precision diagnostics, and regulated life sciences research, while Japan remains important for high-quality translational science, oncology innovation, and regulatory rigor. India offers cost-efficient discovery services, chemistry expertise, bioinformatics talent, and expanding biologics and clinical research capabilities. The United Kingdom remains influential in cancer immunotherapy discovery through genomic medicine initiatives, strong oncology trial infrastructure, and translational research excellence, while France supports immunology, oncology, and cell therapy innovation through strong public research and hospital networks. Canada contributes through strong academic oncology research, immunology expertise, public research funding, and collaborative translational networks, making it attractive for biomarker and early-stage discovery partnerships. Australia is attractive for early-phase oncology research, clinical trial incentives, and strong biomedical governance. Brazil stands out in Latin America for oncology patient diversity, clinical research activity, and scientific capacity, although sponsors must manage regulatory and operational complexity. Italy and Spain provide established oncology research ecosystems, experienced clinical sites, and growing participation in advanced therapy development. Mexico is strengthening its role in clinical research connectivity and regional outsourcing support, supported by proximity to North American sponsors and an improving healthcare research ecosystem. South Korea has emerged as a sophisticated hub for biologics, cell therapy, digital health, and oncology research, supported by advanced hospitals, government innovation programs, and high-quality manufacturing capabilities. Russia has scientific strengths in biology and chemistry but faces elevated geopolitical, regulatory, and supply chain considerations that affect outsourcing decisions.

Actionable Recommendations for Industry Leaders

Industry leaders should treat cancer immunotherapy drug discovery outsourcing as a strategic capability rather than a procurement function. Sponsors should select partners based on validated immunology platforms, oncology domain expertise, data integrity systems, regulatory documentation discipline, and the ability to connect discovery biology with translational biomarkers. A diversified outsourcing network can reduce operational risk, but it must be governed through standardized protocols, quality agreements, cybersecurity requirements, and clear intellectual property provisions. Organizations should prioritize partners with integrated AI and laboratory validation capabilities, especially for target discovery, antibody engineering, neoantigen prediction, immune profiling, and biomarker-led patient segmentation. Leaders should also build decision gates around reproducibility, human-relevant assay performance, toxicity signals, manufacturability, and clinical differentiation. For complex modalities such as cell therapies, bispecifics, and personalized vaccines, early alignment among discovery, CMC, regulatory, and clinical teams is essential. Finally, sponsors should develop ethical and inclusive research frameworks that improve representation in immuno-oncology datasets and support responsible global collaboration.

Research Methodology

This executive summary is developed through a structured secondary research methodology using verified public-domain and institutional sources relevant to cancer immunotherapy, oncology drug discovery, outsourcing models, regulatory science, artificial intelligence in life sciences, and regional biomedical ecosystems. The approach emphasizes triangulation of evidence from peer-reviewed scientific literature, health authority guidance, clinical research registries, government biotechnology strategies, cancer burden publications, public regulatory documents, and recognized healthcare and life sciences policy sources. Insights are synthesized qualitatively to identify technology shifts, regional capabilities, outsourcing drivers, governance considerations, and strategic implications without using market sizing, market share, or forecasting. Data interpretation focuses on observable industry trends, established scientific developments, regulatory expectations, and documented regional capacity indicators. The methodology excludes unverified claims and avoids promotional assertions, ensuring that conclusions are grounded in credible evidence and suitable for executive decision-making in immuno-oncology outsourcing strategy.

Conclusion

Cancer immunotherapy drug discovery outsourcing is evolving into an essential strategy for organizations seeking to advance complex oncology programs while accessing specialized scientific, computational, and translational capabilities. The sector is being shaped by deeper understanding of tumor-immune biology, rapid progress in AI and multi-omics, expanding global research infrastructure, and rising expectations for reproducibility, quality, and regulatory readiness. Regional and country-level dynamics show that mature hubs remain critical for high-end innovation, while emerging regions are expanding their roles through clinical diversity, cost efficiency, and targeted life sciences investment. To succeed, industry leaders must build outsourcing ecosystems that integrate scientific excellence, validated data workflows, secure collaboration, ethical research practices, and early translational planning. In a field where clinical differentiation depends on precision, durability, and safety, the most effective outsourcing strategies will be those that combine global reach with rigorous governance and evidence-based decision-making.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Service Type

  • 7.1. Introduction
  • 7.2. Clinical Development Services
  • 7.3. Data Management And Biostatistics
    • 7.3.1. Bioinformatics
    • 7.3.2. Clinical Data Management
    • 7.3.3. Statistical Analysis
  • 7.4. Manufacturing Support
    • 7.4.1. CMC Optimization
    • 7.4.2. Process Development
  • 7.5. Preclinical Services
    • 7.5.1. Hit And Lead Discovery
    • 7.5.2. Lead Optimization
    • 7.5.3. Preclinical Safety Assessment
    • 7.5.4. Target Identification
  • 7.6. Regulatory Affairs Support
    • 7.6.1. IND Filing Support
    • 7.6.2. Regulatory Strategy Consulting

8. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Therapeutic Modality

  • 8.1. Introduction
  • 8.2. Cancer Vaccines
    • 8.2.1. Dendritic Cell Vaccines
    • 8.2.2. DNA Vaccines
    • 8.2.3. Peptide Vaccines
    • 8.2.4. RNA Vaccines
  • 8.3. CAR T Cell Therapy
    • 8.3.1. BCMA Targeted
    • 8.3.2. CD19 Targeted
  • 8.4. Checkpoint Inhibitors
    • 8.4.1. CTLA-4 Inhibitors
    • 8.4.2. PD-1 Inhibitors
    • 8.4.3. PD-L1 Inhibitors
  • 8.5. Cytokine Therapy
    • 8.5.1. Colony Stimulating Factors
    • 8.5.2. Interferons
    • 8.5.3. Interleukins
  • 8.6. Monoclonal Antibodies
    • 8.6.1. Chimeric
    • 8.6.2. Fully Human
    • 8.6.3. Humanized
    • 8.6.4. Murine
  • 8.7. Oncolytic Virus Therapy
    • 8.7.1. Adenovirus Based
    • 8.7.2. HSV Based
    • 8.7.3. Reovirus Based

9. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Workflow Stage

  • 9.1. Introduction
  • 9.2. Early Discovery
  • 9.3. Lead Optimization
  • 9.4. Preclinical Development

10. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Molecule Type

  • 10.1. Introduction
  • 10.2. Antibody-Based Molecules
  • 10.3. Cell-Based Products
  • 10.4. Gene-Modified Products
  • 10.5. Peptide And Protein Therapeutics
  • 10.6. Small Molecules
  • 10.7. Nucleic Acid-Based Therapeutics

11. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Discovery Platform

  • 11.1. Introduction
  • 11.2. In Vitro Discovery Platforms
  • 11.3. In Vivo Discovery Platforms
  • 11.4. Ex Vivo Platforms
  • 11.5. In Silico Platforms

12. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Outsourcing Model

  • 12.1. Introduction
  • 12.2. Full-Service Outsourcing
  • 12.3. Functional Service Provider Outsourcing
  • 12.4. Project-Based Outsourcing
  • 12.5. Strategic Partnership Outsourcing
  • 12.6. Dedicated Research Team Outsourcing

13. Cancer Immunotherapy Drug Discovery Outsourcing Market, by End User

  • 13.1. Introduction
  • 13.2. Academic Research Institutes
  • 13.3. Biotechnology Companies
  • 13.4. Government Research Institutes
  • 13.5. Pharmaceutical Companies

14. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Therapeutic Area

  • 14.1. Introduction
  • 14.2. Solid Tumors
    • 14.2.1. Lung Cancer
    • 14.2.2. Breast Cancer
    • 14.2.3. Colorectal Cancer
    • 14.2.4. Melanoma
    • 14.2.5. Prostate Cancer
    • 14.2.6. Gastric Cancer
    • 14.2.7. Liver Cancer
    • 14.2.8. Ovarian Cancer
    • 14.2.9. Pancreatic Cancer
    • 14.2.10. Brain Cancer
  • 14.3. Hematologic Malignancies
    • 14.3.1. Lymphoma
    • 14.3.2. Multiple Myeloma
    • 14.3.3. Myelodysplastic Syndromes
    • 14.3.4. Leukemia

15. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Region

  • 15.1. Asia-Pacific
  • 15.2. Europe
  • 15.3. North America
  • 15.4. Latin America
  • 15.5. Africa
  • 15.6. Middle East

16. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Group

  • 16.1. NATO
  • 16.2. G7
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. ASEAN
  • 16.6. GCC

17. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Country

  • 17.1. United States
  • 17.2. China
  • 17.3. Germany
  • 17.4. Japan
  • 17.5. India
  • 17.6. United Kingdom
  • 17.7. France
  • 17.8. Canada
  • 17.9. Australia
  • 17.10. Brazil
  • 17.11. Italy
  • 17.12. Mexico
  • 17.13. South Korea
  • 17.14. Russia
  • 17.15. Spain

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2025
  • 18.2. FPNV Positioning Matrix, 2025
  • 18.3. Market Concentration Analysis, 2025
    • 18.3.1. Concentration Ratio (CR)
    • 18.3.2. Herfindahl Hirschman Index (HHI)
  • 18.4. Recent Developments & Impact Analysis, 2025
  • 18.5. Product Portfolio Analysis, 2025
  • 18.6. Benchmarking Analysis, 2025

19. Company Profiles

  • 19.1. AbCellera Biologics Inc.
  • 19.2. Absci Corporation
  • 19.3. Adimab, LLC
  • 19.4. Alloy Therapeutics, Inc.
  • 19.5. Anthem Biosciences Limited
  • 19.6. Aragen Life Sciences Limited
  • 19.7. Champions Oncology, Inc.
  • 19.8. Charles River Laboratories International, Inc.
  • 19.9. ChemDiv, Inc.
  • 19.10. Creative Biolabs, Inc.
  • 19.11. Curia Global, Inc.
  • 19.12. Domainex Ltd.
  • 19.13. Enamine Ltd.
  • 19.14. Eurofins Scientific SE
  • 19.15. Evotec SE
  • 19.16. GenScript Biotech Corporation
  • 19.17. ImmunoPrecise Antibodies Ltd.
  • 19.18. InSilico Medicine
  • 19.19. JSR Corporation
  • 19.20. NovAliX SAS
  • 19.21. Pharmaron Beijing Co., Ltd.
  • 19.22. ProMab Biotechnologies, Inc.
  • 19.23. Reaction Biology Corporation
  • 19.24. Sai Life Sciences Limited
  • 19.25. Schrodinger, Inc.
  • 19.26. Selvita S.A.
  • 19.27. Shanghai Medicilon Inc.
  • 19.28. Sygnature Discovery Limited
  • 19.29. Syngene International Limited
  • 19.30. Taconic Biosciences, Inc.
  • 19.31. TCG Lifesciences Limited
  • 19.32. The Jackson Laboratory
  • 19.33. WuXi AppTec Co., Ltd.
  • 19.34. WuXi Biologics (Cayman) Inc.
  • 19.35. XtalPi Holdings Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY THERAPEUTIC MODALITY, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY THERAPEUTIC MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW STAGE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PLATFORM, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY OUTSOURCING MODEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY OUTSOURCING MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 29. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CLINICAL DEVELOPMENT SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CLINICAL DEVELOPMENT SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CLINICAL DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DATA MANAGEMENT AND BIOSTATISTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DATA MANAGEMENT AND BIOSTATISTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DATA MANAGEMENT AND BIOSTATISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOINFORMATICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOINFORMATICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIOINFORMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CLINICAL DATA MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CLINICAL DATA MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CLINICAL DATA MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL STATISTICAL ANALYSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL STATISTICAL ANALYSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL STATISTICAL ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MANUFACTURING SUPPORT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MANUFACTURING SUPPORT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MANUFACTURING SUPPORT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CMC OPTIMIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CMC OPTIMIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CMC OPTIMIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PROCESS DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PROCESS DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PROCESS DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PRECLINICAL SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PRECLINICAL SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PRECLINICAL SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HIT AND LEAD DISCOVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HIT AND LEAD DISCOVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HIT AND LEAD DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LEAD OPTIMIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LEAD OPTIMIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LEAD OPTIMIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PRECLINICAL SAFETY ASSESSMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PRECLINICAL SAFETY ASSESSMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PRECLINICAL SAFETY ASSESSMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TARGET IDENTIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TARGET IDENTIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TARGET IDENTIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL REGULATORY AFFAIRS SUPPORT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL REGULATORY AFFAIRS SUPPORT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL REGULATORY AFFAIRS SUPPORT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IND FILING SUPPORT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IND FILING SUPPORT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IND FILING SUPPORT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL REGULATORY STRATEGY CONSULTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL REGULATORY STRATEGY CONSULTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL REGULATORY STRATEGY CONSULTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CANCER VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DENDRITIC CELL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DENDRITIC CELL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DENDRITIC CELL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DNA VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DNA VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DNA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PEPTIDE VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PEPTIDE VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PEPTIDE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL RNA VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL RNA VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL RNA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CAR T CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CAR T CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CAR T CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BCMA TARGETED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BCMA TARGETED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BCMA TARGETED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CD19 TARGETED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CD19 TARGETED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CD19 TARGETED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CTLA-4 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CTLA-4 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CTLA-4 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PD-1 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PD-1 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PD-1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CYTOKINE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CYTOKINE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CYTOKINE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL COLONY STIMULATING FACTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL COLONY STIMULATING FACTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL COLONY STIMULATING FACTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL INTERFERONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL INTERFERONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL INTERFERONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL INTERLEUKINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL INTERLEUKINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL INTERLEUKINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CHIMERIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CHIMERIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CHIMERIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL FULLY HUMAN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL FULLY HUMAN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL FULLY HUMAN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL HUMANIZED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL HUMANIZED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL HUMANIZED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL MURINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL MURINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL MURINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ONCOLYTIC VIRUS THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ONCOLYTIC VIRUS THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ONCOLYTIC VIRUS THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ADENOVIRUS BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ADENOVIRUS BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ADENOVIRUS BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL HSV BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL HSV BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL HSV BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL REOVIRUS BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL REOVIRUS BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL REOVIRUS BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL EARLY DISCOVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL EARLY DISCOVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL EARLY DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL LEAD OPTIMIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL LEAD OPTIMIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL LEAD OPTIMIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL PRECLINICAL DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL PRECLINICAL DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL PRECLINICAL DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANTIBODY-BASED MOLECULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL ANTIBODY-BASED MOLECULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANTIBODY-BASED MOLECULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL CELL-BASED PRODUCTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL CELL-BASED PRODUCTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL CELL-BASED PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL GENE-MODIFIED PRODUCTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL GENE-MODIFIED PRODUCTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL GENE-MODIFIED PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL PEPTIDE AND PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL PEPTIDE AND PROTEIN THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL PEPTIDE AND PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL SMALL MOLECULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL SMALL MOLECULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL SMALL MOLECULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL NUCLEIC ACID-BASED THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL NUCLEIC ACID-BASED THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL NUCLEIC ACID-BASED THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL IN VITRO DISCOVERY PLATFORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL IN VITRO DISCOVERY PLATFORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL IN VITRO DISCOVERY PLATFORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL IN VIVO DISCOVERY PLATFORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL IN VIVO DISCOVERY PLATFORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL IN VIVO DISCOVERY PLATFORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL EX VIVO PLATFORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL EX VIVO PLATFORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL EX VIVO PLATFORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL IN SILICO PLATFORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL IN SILICO PLATFORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL IN SILICO PLATFORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY OUTSOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL FULL-SERVICE OUTSOURCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL FULL-SERVICE OUTSOURCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL FULL-SERVICE OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL FUNCTIONAL SERVICE PROVIDER OUTSOURCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL FUNCTIONAL SERVICE PROVIDER OUTSOURCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL FUNCTIONAL SERVICE PROVIDER OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL PROJECT-BASED OUTSOURCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL PROJECT-BASED OUTSOURCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL PROJECT-BASED OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL STRATEGIC PARTNERSHIP OUTSOURCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL STRATEGIC PARTNERSHIP OUTSOURCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL STRATEGIC PARTNERSHIP OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL DEDICATED RESEARCH TEAM OUTSOURCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL DEDICATED RESEARCH TEAM OUTSOURCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL DEDICATED RESEARCH TEAM OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL ACADEMIC RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL ACADEMIC RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL ACADEMIC RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL GOVERNMENT RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL GOVERNMENT RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL GOVERNMENT RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL SOLID TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL SOLID TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL SOLID TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL MELANOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL MELANOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL PROSTATE CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL PROSTATE CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL PROSTATE CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL GASTRIC CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL GASTRIC CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 220. GLOBAL GASTRIC CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL LIVER CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL LIVER CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 223. GLOBAL LIVER CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL OVARIAN CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL OVARIAN CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 226. GLOBAL OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL PANCREATIC CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL PANCREATIC CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 229. GLOBAL PANCREATIC CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL BRAIN CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL BRAIN CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 232. GLOBAL BRAIN CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 235. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 236. GLOBAL LYMPHOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 237. GLOBAL LYMPHOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 238. GLOBAL LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 241. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 242. GLOBAL MYELODYSPLASTIC SYNDROMES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL MYELODYSPLASTIC SYNDROMES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 244. GLOBAL MYELODYSPLASTIC SYNDROMES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. GLOBAL LEUKEMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 246. GLOBAL LEUKEMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 247. GLOBAL LEUKEMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 248. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT AND BIOSTATISTICS, 2018-2032 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MANUFACTURING SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CAR T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CYTOKINE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY OUTSOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT AND BIOSTATISTICS, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MANUFACTURING SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CAR T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CYTOKINE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY OUTSOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 292. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT AND BIOSTATISTICS, 2018-2032 (USD MILLION)
  • TABLE 294. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MANUFACTURING SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 296. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 298. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CAR T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 300. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CYTOKINE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 302. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2032 (USD MILLION)
  • TABLE 304. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY OUTSOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 308. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 310. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 311. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 312. LATIN AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 313. LATIN AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. LATIN AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT AND BIOSTATISTICS, 2018-2032 (USD MILLION)
  • TABLE 315. LATIN AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MANUFACTURING SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 316. LATIN AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 317. LATIN AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 318. LATIN AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 319. LATIN AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 320. LATIN AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CAR T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 321. LATIN AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 322. LATIN AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CYTOKINE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 323. LATIN AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 324. LATIN AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2032 (USD MILLION)
  • TABLE 325. LATIN AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 326. LATIN AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 327. LATIN AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 328. LATIN AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY OUTSOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 329. LATIN AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 330. LATIN AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 331. LATIN AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 332. LATIN AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 333. AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 334. AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET